skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Spebrutinib (Code C97037)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Spebrutinib

Definition: An orally bioavailable, selective inhibitor of Bruton's agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity. Upon administration, spebrutinib targets and covalently binds to BTK, thereby preventing its activity. By irreversibly inhibiting BTK, administration of this agent may lead to an inhibition of B cell receptor (BCR) signaling and may inhibit cell proliferation of B-cell malignancies. BTK, a cytoplasmic tyrosine kinase and member of the Tec family of kinases, plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.

Display Name: BTK Inhibitor CC-292

Label: Spebrutinib

NCI Thesaurus Code: C97037 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C3642455  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
2-Propenamide, N-(3-((5-fluoro-2-((4-(2-methoxyethoxy)phenyl)amino)-4-pyrimidinyl)amino)phenyl)-
Bruton's Tyrosine Kinase Inhibitor CC-292
BTK Inhibitor CC-292

External Source Codes: 
CAS Registry Number 1202757-89-8 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 700570
PDQ Open Trial Search ID 700570 (check for NCI PDQ open clinical trial info)
UMLS CUI C3642455

Other Properties:
     Name Value (qualifiers indented underneath)
code C97037
Contributing_Source CTRP
Contributing_Source FDA
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom